Last reviewed · How we verify
NCT02432937
A Double-Blind, Randomized, Placebo-Controlled, Parallel-Group, Phase III Study of Corever for the Treatment of Hypertension
Phase 3 trial testing Corever in Hypertension in 134 participants. Completed in 1 August 2016.
1 June 2016
Quick facts
| Lead sponsor | TSH Biopharm Corporation Limited |
|---|---|
| Phase | Phase 3 |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | double |
| Primary purpose | treatment |
| Enrollment | 134 |
| Start date | 1 January 2015 |
| Primary completion | 1 June 2016 |
| Estimated completion | 1 August 2016 |
| Sites | 8 locations across Taiwan |
Drugs / interventions tested
- Corever — full drug profile →
Conditions studied
- Hypertension — all drugs for Hypertension →
Sponsor
TSH Biopharm Corporation Limited — full company profile →
Who can join
Adults 20 to 90, any sex, with Hypertension. Patients with the condition only — healthy volunteers not accepted.
What's being measured
Primary outcomes are the specific endpoints the trial is designed to prove or disprove.
-
Seated Office SBP reduction (SBP each visit-SBP visit 2)
Time frame: 8 weeks
To compare the change in office SBP measurements by cuff assessments after 8 weeks of treatment
Sponsor's own description
The study primarily aims to compare the effects of two doses of Corever with placebo in patients with hypertension.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Extended-Release Carvedilol in the Treatment of Hypertension: A Double-Blind, Randomized, Placebo-Controlled Trial.
Wang KL, Fang CY, Lai WT, Wang TD, et al · · 2021 · cited 1× · PMID 33716461 · DOI 10.6515/acs.202103_37(2).20200914b
Verify or expand the search:
- PubMed search for NCT02432937
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Hypertension
Currently open trials in the same condition.
- NCT07413159 — The "Check, Monitor, Control Hypertension" Study is a 24-month Randomized Trial in Houston Targeting African Americans A · NA · recruiting
- NCT07361276 — Observational Study That Will Evaluate Treatment Patterns in the Management of Hypertension in the Public Primary Care S · recruiting
- NCT07238556 — A Novel Digital Tool Physicians Can Use to Prescribe Exercise to Patients With Cardiovascular Disease Risk Factors · NA · recruiting
- NCT07238400 — Cardiac Effects of Mineralocorticoid Receptor Antagonism After Preeclampsia · Phase 2 · recruiting
- NCT07135505 — Early Time-Restricted Eating in Older Adults With Hypertension · NA · recruiting
Other TSH Biopharm Corporation Limited trials
Trials by the same sponsor.
- NCT05180305 — A Study to Assess Mitomic Prostate Test for Prostate Cancer Screening · unknown
- NCT03674658 — Propafenone in the Treatment of Atrial Fibrillation · NA · completed
- NCT03401502 — A TSHRN1201 Sub-study-To Evaluate the Effects of add-on Ranolazine on Exercise Tolerance and Angina Frequency · NA · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT02432937 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by TSH Biopharm Corporation Limited
- Last refreshed: 2 November 2016
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02432937.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing